New stock news | DiZhe Medicine (688192.SH) Hong Kong IPO prospectus is invalid.
The Hong Kong IPO prospectus submitted by Di Zhe (Jiangsu) Pharmaceutical Co., Ltd. on January 23, 2026, expired after 6 months on July 23, 2026.
Dezhe (Jiangsu) Pharmaceutical Co., Ltd. (referred to as Dezhe Pharmaceutical (688192.SH)) submitted its Hong Kong IPO prospectus on January 23, 2026, which expired after 6 months on July 23, 2026, with Goldman Sachs and Huatai International as its joint sponsors.
According to the prospectus, Dezhe Pharmaceutical is a commercial-stage biopharmaceutical company with a focus on the treatment of oncology and hematologic diseases. Their listed product, Shuwozhe, is the only globally approved small molecule epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of EGFR exon 20 insertion mutation-positive lung cancer.
For the fiscal years of 2023, 2024, and the nine months ending September 30, 2025, the company achieved revenues of 91.289 million yuan, 360 million yuan, and 586 million yuan respectively.
Related Articles
HK Stock Market Move | INNOSCIENCE (02577) rose over 3% as the demand for gallium nitride power devices is expected to increase. The company will benefit from the construction of 800V artificial intelligence data centers.
HK Stock Market Move | XUNCE (03317) surged over 8%, leading the AI application sector. Revenue skyrocketed 389% in the first half of the year, and the commercialization process of the token economy far exceeded expectations.
HK Stock Market Move | IMPRO PRECISION (01286) rose over 6% during trading as the company raised its full-year performance growth guidance. Expectations for AI-related products are expected to continue strong growth.
HK Stock Market Move | INNOSCIENCE (02577) rose over 3% as the demand for gallium nitride power devices is expected to increase. The company will benefit from the construction of 800V artificial intelligence data centers.
HK Stock Market Move | XUNCE (03317) surged over 8%, leading the AI application sector. Revenue skyrocketed 389% in the first half of the year, and the commercialization process of the token economy far exceeded expectations.
HK Stock Market Move | IMPRO PRECISION (01286) rose over 6% during trading as the company raised its full-year performance growth guidance. Expectations for AI-related products are expected to continue strong growth.
RECOMMEND
